Cipla Technologies,  a wholly owned step-down subsidiary of Cipla Limited and Pulmatrix have completed an amendment to the agreement for the development and commercialization of Pulmazole.

The parties have now agreed to: Terminate the Phase 2b clinical trial for development of Pulmazole by 30th July, 2024; and Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America.